Related references
Note: Only part of the references are listed.Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA
Giovanni Palladini et al.
BLOOD (2020)
Fifteen year overall survival rates after autologous stem cell transplantation for AL amyloidosis
Surbhi Sidana et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Ten-year survivors in AL amyloidosis: characteristics and treatment pattern
Eli Muchtar et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Meletios A. Dimopoulos et al.
LANCET (2019)
Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time
M. Hasib Sidiqi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment
Morie A. Gertz
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity
T. Jelinek et al.
HEMATOLOGICAL ONCOLOGY (2017)
Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response
Martha Grogan et al.
HEART (2017)
Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis
Surbhi Sidana et al.
PLOS ONE (2017)
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis
Vaishali Sanchorawala et al.
BLOOD (2017)
Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy
Efstathios Kastritis et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death
Eli Muchtar et al.
BLOOD (2017)
Recent advances in the management of AL Amyloidosis
Efstathios Kastritis et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines
Jean D. Sipe et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2016)
Randomized phase 2 trial of ixazomib and dexamethasone in relapsed multiple myeloma not refractory to bortezomib
Shaji K. Kumar et al.
BLOOD (2016)
What is new in diagnosis and management of light chain amyloidosis?
Giovanni Palladini et al.
BLOOD (2016)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
P. Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Safety and Efficacy of Carfilzomib (CFZ) in Previously-Treated Systemic Light-Chain (AL) Amyloidosis
Adam D. Cohen et al.
BLOOD (2016)
Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis
Gregory P. Kaufman et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement
Angela Dispenzieri et al.
MAYO CLINIC PROCEEDINGS (2015)
Guidelines on the diagnosis and investigation of AL amyloidosis
Julian D. Gillmore et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Guidelines on the management of AL amyloidosis
Ashutosh D. Wechalekar et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Novel strategies for the diagnosis and treatment of cardiac amyloidosis
Giovanni Palladini et al.
EXPERT REVIEW OF CARDIOVASCULAR THERAPY (2015)
A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis
Giovanni Palladini et al.
BLOOD (2014)
Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis
Donna E. Reece et al.
BLOOD (2014)
Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients
G. Palladini et al.
LEUKEMIA (2014)
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide
Giovanni Palladini et al.
ANNALS OF HEMATOLOGY (2012)
New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes
Giovanni Palladini et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis
R. L. Comenzo et al.
LEUKEMIA (2012)
Amyloidosis: Pathogenesis and New Therapeutic Options
Giampaolo Merlini et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs
Angela Dispenzieri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2010)
Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial
Vaishali Sanchorawala et al.
BLOOD (2007)
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis
Angela Dispenzieri et al.
BLOOD (2007)
The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL)
G Palladini et al.
BLOOD (2005)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis
A Dispenzieri et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2003)
A modified high-dose dexamethasone regimen for primary systemic (AL) amyloidosis
G Palladini et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Share Paper
